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Hyperthermic intraperitoneal chemotherapy: Another choice for advanced
gastric cancer?Gastric cancer is one of the most common cancers
throughout the world.1 Overall, the prognosis of gastric cancer
is very poor, and surgery is the main treatment modality for
this deadly disease.2 Standard gastrectomy with D2 dissection
is the principal surgical procedure performed with curative
intent.3 However, survival rates after curative surgery for
gastric cancer are disappointing.2 Many patients with gastric
cancer have serosal invasion and experience recurrence with
peritoneal carcinomatosis.2 Although adjuvant systemic che-
motherapy is used for treating advanced stages of gastric
cancer,4,5 the toxicity of systemic chemotherapy is intolerable
for some patients. In 1980, Spratt et al6 reported that a pseu-
domyxoma peritonei patient with peritoneal seeding from
distal pancreas was treated by surgical resection of the primary
lesion and his peritoneal metastases were treated by hyper-
thermic intraperitoneal chemotherapy (HIPEC). The HIPEC
has the advantage of increasing the concentration of chemo-
therapeutic agents locally administered into the peritoneum
with fewer systemic side effects than that seen with systemic
chemotherapy. Sun et al7 analyzed 10 randomized controlled
trials from PubMed, Embase, Cochrane Database of System-
atic Reviews, and Cochrane Central Register of Controlled
Trials, which revealed that HIPEC may improve overall sur-
vival after surgical resection for advanced gastric cancer.
Furthermore, it helps to prevent peritoneal recurrence among
patients with serosal invasion. However, the small number of
patients enrolled and publication biases are areas of concern
for these studies, and suggest that further research is necessary.
In the current issue of the Journal of the Chinese Medical
Association, Kang et al8 analyzed 172 gastric cancer patients
with serosal invasion and revealed a longer time for recurrence
of carcinomatosis and a longer survival rate in the curative
gastrectomy plus HIPEC group than in the curative gas-
trectomy alone group. There was no significant difference in
the rate of complications between the two prophylactic groups.
The study performed by Kang et al8 further supports the
benefit of HIPEC as an adjuvant therapy for gastric cancer
patients with serosal invasion.
Although several studies have demonstrated benefits in terms
of both tumor response and survival, there is still no absolute
consensus regarding the most effective regimen of admin-
istration. To assist in the resolution of this issue, the possible side1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.04.007effects of the regimen used should also be considered. The
combination of heat and drug toxicity may lead to more com-
plications, such as anastomotic leakage, intra-abdominal
abscess, wound infection, pulmonary edema, and adult respi-
ratory distress syndrome, especially when used after a palliative
surgery.8 In the study reported byKang et al,8 the patient number
is small and the design is not randomized. Therefore, further
prospective randomized trials are needed to determine the def-
inite role of HIPEC as adjuvant chemotherapy for advanced
gastric cancer patients with serosal invasion.References
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